Form 4: Sensei Biotherapeutics Director Kristian Humer Granted 19,000 Stock Options

Sensei Biotherapeutics, Inc. Director Kristian Humer was granted 19,000 stock options with an exercise price of $0.3202, vesting over one year.

Summary

• Kristian Humer, a Director of Sensei Biotherapeutics, Inc. (SNSE), was granted 19,000 stock options on May 21, 2025.
• The exercise price for these options is $0.3202 per share.
• The options vest in 12 equal monthly installments over a one-year period, becoming fully vested on May 21, 2026, or on the date of the Company's next annual stockholder meeting, whichever comes first, subject to continuous service.
• The expiration date for these stock options is May 20, 2035.
• Following this transaction, Kristian Humer directly beneficially owns 19,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard and generally positive corporate governance action, aligning the director's incentives with shareholder interests. It does not indicate any immediate operational or financial performance issues, nor does it suggest extraordinary positive developments beyond standard compensation practices.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• The exercise price of $0.3202 is clearly defined, providing transparency on the potential cost to exercise.

Future Outlook

The stock options granted to Director Kristian Humer are set to vest over a one-year period, with full vesting expected by May 21, 2026, or at the company's next annual stockholder meeting, contingent on continuous service.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to align their interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The option grant aims to align the director's interests with shareholders, potentially leading to better long-term performance and value creation.

Next Steps

• The stock options will continue to vest monthly over the next year, subject to Kristian Humer's continuous service.
• Kristian Humer may choose to exercise the vested options at any time before the expiration date of May 20, 2035.

Key Dates

Keywords

Sensei Biotherapeutics, SNSE, Stock Option, Director Compensation, Form 4, Insider Transaction, Equity Grant, Kristian Humer